Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine

Annals of Pharmacotherapy

Volumn 35, Issue 12, 2001, Pages 1517-1522

  Schillevoort, Igor ^a   De Boer, Anthonius ^a   Herings, Ron M C ^a   Roos, Raymund A C ^b   Jansen, Paul A F ^c   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atypical antipsychotics; Extrapyramidal syndromes; Selective prescribing

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; DEXETIMIDE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; ORPHENADRINE; PROCYCLIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PIRENZEPINE; RISK FACTORS; RISPERIDONE;

EID: 0035663068     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A068     Document Type: Article

References (25)

1. The history of clozapine
2. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and metaregression analysis
3. Risperidone versus typical antipsychotic medication for schizophrenia
4. Variability in patterns of drug use
5. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia
6. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
7. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme
8. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life
9. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs
10. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects
11. Olanzapine for schizophrenia
12. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: A double-blind, multi-center trial
13. 2 receptors
14. Serotonin-dopamine interaction and its relevance to schizophrenia
15. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs
16. When does Parkinson’s disease begin?
17. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
18. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism
19. Switching antipsychotic therapies
20. Assessment of EPS and tardive dyskinesia in clinical trials
21. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients
22. Risk factors for the development of neuroleptic induced akathisia